HALP score is a scoring system consisting of hemoglobin, albumin, lymphocyte and platelet. It is different from other prognostic markers because it provides information about both inflammation and immunonutrition status. This study aims to evaluate the severity of the disease and the level of prognosis in patients diagnosed with acute diverticulitis. 190 patients diagnosed with acute diverticulitis between January 2017 and June 2023 were included in the study. The patients were divided into two separate groups according to the Hinchey classification. The prognostic effect of inflammatory markers and HALP score was examined. The median values of C-reactive protein, white blood cell count, neutrophil count, HALP score, and hospitalization duration were significantly higher in patients diagnosed with complicated diverticulitis than in those diagnosed with uncomplicated diverticulitis. (p < 0.001, p = 0.045, p = 0.004, p < 0.001 and p < 0.001, respectively). The distinguishing feature of the HALP score in predicting the complexity of the diagnosis of diverticulitis was evaluated using ROC analysis. Area Under Curve (AUC) value was found to be 0.723 (p < 0.001). According to the ROC curve, the sensitivity and specificity for the cut-off value of HALP score ≤44.1 were 66.7 % and 75.0 %, respectively. HALP score is an inexpensive parameter that can be used safely to determine the severity and prognosis of acute diverticulitis.
Background: Autotaxin (ATX) is a nucleotide enzyme linked to cell growth, differentiation and migration. This study investigated serum levels of ATX in colorectal cancer (CRC). Methods: The study i... Plain language summary What is this summary about? Here, we summarize the results from ‘The diagnostic value of serum autotaxin level in colorectal cancer’ study, published in Biomarkers in Medicin... Tweetable abstract Serum autotaxin level might be a potential biomarker in the diagnosis and follow-up of colorectal cancer.
Isolated hyperthermic limb perfusion (ILP) is a limb-salvage technique used in the treatment of malignant melanoma and soft tissue sarcomas with in-transit or locally advanced disease. ILP allows regional administration of high-dose chemotherapy with minimal systemic toxicity. This study aims to evaluate postoperative complications and identify predictive factors influencing outcomes in patients undergoing ILP. We retrospectively analyzed 49 patients with malignant melanoma or extremity soft tissue sarcoma who underwent ILP at a single tertiary center between 2014 and 2024. Complications were classified using the Clavien-Dindo system; toxicity was graded via the Wieberdink scale. Logistic regression and univariate analyses were used to evaluate clinical, surgical, and laboratory parameters predictive of severe complications, toxicity, and mortality. Of the patients, 32 (65.3%) experienced complications, primarily within the first 3 postoperative days. Severe complications (Clavien-Dindo grade ≥ 3) occurred in 11 patients (22.4%). Severe regional toxicity (Wieberdink grade ≥ 4) was observed in 6.1%. Early mortality occurred in 3 cases. Preoperative and postoperative albumin levels, along with C-reactive protein levels on postoperative days 3 and 5, were significantly associated with severe complications. No significant relationship was found between modified Systemic Inflammation Scores and postoperative outcomes. ILP remains a valuable regional treatment option for carefully selected patients with advanced melanoma and extremity soft tissue sarcoma. Preoperative nutritional status and early postoperative inflammatory markers, particularly albumin and C-reactive protein, may serve as valuable predictors for adverse outcomes. Optimization of these parameters could improve postoperative recovery and treatment planning.
Introduction: Spleen volume (SV) may increase during systemic chemotherapy, potentially reflecting treatment-related hepatic, hematological, and immune alterations. However, the clinical significance of SV changes during neoadjuvant chemotherapy (NAC) for gastric cancer remains unclear. This study evaluated SV changes during NAC and their associations with radiological response and overall survival (OS). Methods: This retrospective cohort study included 111 patients with gastric adenocarcinoma who received NAC followed by curative-intent gastrectomy. SV was measured on computed tomography before and after NAC using semiautomated volumetric segmentation. Relative SV change (ΔSV%) was calculated. Radiological response was assessed according to RECIST 1.1. Associations of ΔSV% with objective response and OS were evaluated using logistic and Cox regression analyses, respectively. Results: Mean SV increased significantly from 250.59 ± 98.11 to 335.40 ± 126.81 cm3 (p < 0.001), with a mean ΔSV% of 34.53 ± 15.72%. SV increased in 108 patients (97.3%). Objective response was observed in 56 patients (50.5%). ΔSV% did not differ between responders and nonresponders (34.05 ± 15.66% vs. 35.03 ± 15.90%; p = 0.730) and was not associated with objective response after multivariable adjustment (OR per 10% increase, 0.932; 95% CI, 0.715–1.207; p = 0.578). ΔSV% was also not associated with OS (adjusted HR, 1.031; 95% CI, 0.859–1.236; p = 0.745). Conclusions: SV increased markedly in nearly all patients during NAC for gastric cancer. However, the magnitude of this increase was not associated with radiological response or OS, suggesting that splenic enlargement during NAC may represent a treatment-associated phenomenon rather than a marker of antitumor efficacy or prognosis.